Precision Biosciences (DTIL) Cash from Investing Activities (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Cash from Investing Activities of -$114000.0 for Q1 2026, up 63.69% year-over-year from -$69642.0 in Q1 2025, and up 64.92% quarter-over-quarter from -$325000.0 in Q4 2025.
Precision Biosciences (DTIL) Cash from Investing Activities (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Cash from Investing Activities for 9 consecutive years, with -$114000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 63.69% year-over-year to -$114000.0; the TTM figure through Mar 2026 stood at -$434000.0 (up 13.72% YoY), while the FY2025 annual figure was -$634000.0, down 194.88% from the prior year.
- Cash from Investing Activities grew to -$114000.0 in Q1 2026 per DTIL's latest filing, from -$325000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $7.6 million in Q3 2023 and bottomed at -$1.1 million in Q3 2022.
- Historically, Cash from Investing Activities has averaged $91000.0 across 5 years, with a median of -$114000.0 in 2026.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities surged 793.94% — and 2025, when it plunged 1107.69%.
- Precision Biosciences' Cash from Investing Activities stood at -$632000.0 in 2022, then surged by 106.65% to $42000.0 in 2023, then tumbled by 330.95% to -$97000.0 in 2024, then tumbled by 235.05% to -$325000.0 in 2025, then jumped by 64.92% to -$114000.0 in 2026.
- Business Quant data shows DTIL's Cash from Investing Activities at -$114000.0 in Q1 2026, -$325000.0 in Q4 2025, and $17000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - | 1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1,000.00 |
| Jun 30, 2026 | 1,000.00 |
| Mar 31, 2026 | -114,000.00 |
| Mar 31, 2026 | -114,000.00 |
| Dec 31, 2025 | -325,000.00 |
| Dec 31, 2025 | -325,000.00 |
| Sep 30, 2025 | 17,000.00 |
| Sep 30, 2025 | 17,000.00 |
| Jun 30, 2025 | -12,000.00 |
| Jun 30, 2025 | -12,000.00 |
| Mar 31, 2025 | -314,000.00 |
| Mar 31, 2025 | -314,000.00 |
| Dec 31, 2024 | -97,000.00 |
| Dec 31, 2024 | -97,000.00 |
| Sep 30, 2024 | -64,000.00 |
| Sep 30, 2024 | -64,000.00 |
| Jun 30, 2024 | -28,000.00 |
| Jun 30, 2024 | -28,000.00 |
| Mar 31, 2024 | -26,000.00 |
| Mar 31, 2024 | -26,000.00 |